BioElectronics Chairman Highlights Sales Growth, Strategic Progress in Shareholder Update

BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from Chairman Richard Staelin, PhD, detailing sales growth, cost controls, and strategic milestones. The company reported a small profit for calendar year 2025, attributed to disciplined cost management including office relocation and staff reductions.

Revenue-generating initiatives include targeted advertising campaigns aimed at medical professionals and healthcare providers to expand clinical awareness of RecoveryRx among surgeons, pain specialists, and rehabilitation providers. Consumer-focused social media advertising targeting Generation X is also underway to boost brand visibility for drug-free chronic musculoskeletal pain solutions.

BioElectronics continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The goal is to participate in a postoperative clinical study that could support qualification for reimbursement under the federal NO PAIN Act initiative, which the company believes represents a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies.

The net effect of these efforts is an increase in monthly sales in both over-the-counter and professional markets. Internationally, BioElectronics is pursuing arbitration proceedings with a former distributor in Singapore and China, working with legal counsel and funders to protect intellectual property and contractual rights.

A significant development is the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, and BioElectronics received Electrome's initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This milestone provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.

Despite challenges faced by emerging medical technology companies, Chairman Staelin expressed encouragement from growing interest in non-drug pain management solutions and the long-term potential of the company's technology platforms. BioElectronics is positioned within the evolving electroceutical and non-opioid pain management markets, with initiatives supporting sustainable growth.